COVID-19 mRNA Vaccine (SYS6006)
COVID-19 Prevention
MarketedConditional Approval
Key Facts
Indication
COVID-19 Prevention
Phase
Marketed
Status
Conditional Approval
About CSPC Innovation Pharmaceutical
CSPC Innovation Pharmaceutical's mission is to establish CSPC as a global, innovation-driven biopharmaceutical leader by developing and commercializing novel therapeutics. Its key achievement is building a substantial and maturing clinical pipeline, primarily in oncology, which is now advancing into late-stage trials and contributing to the parent group's valuation of over $45 billion. The strategy centers on leveraging internal R&D across multiple modalities, strategic external partnerships, and the parent company's formidable commercial and manufacturing scale to efficiently bring differentiated medicines to the large Chinese and international markets.
View full company profileTherapeutic Areas
Other COVID-19 Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Intranasal COVID Vaccine | Virpax Pharmaceuticals | Research |
| COVID-19 Vaccine Trials | DM Clinical Research | Not Specified |
| SARS-CoV-2 Vaccine | Epygen Biotech | Not Disclosed |
| IRT Platform (e.g., COVID-19) | Biological Mimetics | Research/Pre-clinical |
| COMIRNATY® (BNT162b2) | Fosun Pharma | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| Recombinant Protein COVID-19 Vaccine | Sinopharm | Approved |
| Recombinant COVID-19 Vaccine (CHO Cell) | Zhifei Biological Products | Marketed |
| SARS-CoV-2 Inactivated Vaccine | Hualan Biological Engineering | Marketed |
| CoronaVac | Sinovac Biotech | Approved |